JP2011515490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515490A5 JP2011515490A5 JP2011502032A JP2011502032A JP2011515490A5 JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5 JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011502032 A JP2011502032 A JP 2011502032A JP 2011515490 A5 JP2011515490 A5 JP 2011515490A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- cldc
- adjuvanted
- fish
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 13
- 238000000034 method Methods 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 9
- 241000251468 Actinopterygii Species 0.000 claims 8
- -1 cationic lipid Chemical class 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 241000271566 Aves Species 0.000 claims 3
- 102000035122 glycosylated proteins Human genes 0.000 claims 3
- 108091005608 glycosylated proteins Proteins 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 241000589601 Francisella Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 229940037003 alum Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 229960003971 influenza vaccine Drugs 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000712431 Influenza A virus Species 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 241001061127 Thione Species 0.000 claims 1
- 208000034784 Tularaemia Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000009285 allergic inflammation Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims 1
- 229940124739 inactivated trivalent influenza vaccine Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960003085 meticillin Drugs 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3938108P | 2008-03-25 | 2008-03-25 | |
| US61/039,381 | 2008-03-25 | ||
| PCT/US2009/038307 WO2009120811A1 (en) | 2008-03-25 | 2009-03-25 | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011515490A JP2011515490A (ja) | 2011-05-19 |
| JP2011515490A5 true JP2011515490A5 (cg-RX-API-DMAC10.html) | 2012-05-17 |
| JP5759890B2 JP5759890B2 (ja) | 2015-08-05 |
Family
ID=40791017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502032A Expired - Fee Related JP5759890B2 (ja) | 2008-03-25 | 2009-03-25 | カチオン性脂質−ｄｎａ複合体（ｃｌｄｃ）の投与による免疫応答の増強 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8945590B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2257306B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5759890B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI0910036B8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2719614C (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009120811A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0910036B8 (pt) | 2008-03-25 | 2021-05-25 | Juvaris Biotherapeutics Inc | kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina |
| CA2761736C (en) * | 2009-05-14 | 2017-09-26 | Bayer Animal Health Gmbh | Enhanced immune response in avian species |
| US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
| SI2654785T1 (sl) * | 2010-12-22 | 2019-06-28 | Bayer Intellectual Property Gmbh | Ojačan imunski odziv pri govejih vrstah |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| CA2940794C (en) | 2014-02-28 | 2022-05-31 | Bayer Animal Health Gmbh | Immunostimulatory plasmids |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016081911A2 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| DK3328423T3 (da) * | 2015-07-31 | 2021-07-26 | Bayer Animal Health Gmbh | Forbedret immunrespons hos fisk |
| TW201718001A (zh) | 2015-07-31 | 2017-06-01 | 拜耳動物保健有限公司 | 豬物種中增強之免疫反應 |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| US10918709B2 (en) * | 2016-10-31 | 2021-02-16 | Eyegene Inc. | Immune modulator and vaccine composition containing the same |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
| US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US6121247A (en) * | 1996-03-29 | 2000-09-19 | The Johns Hopkins University | Therapy for allergic diseases |
| CA2295740A1 (en) | 1997-07-08 | 1999-01-21 | Chiron Corporation | Use of submicron oil-in-water emulsions with dna vaccines |
| PT1009413E (pt) * | 1997-09-05 | 2007-05-31 | Univ California | Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma. |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| US20090208781A1 (en) * | 2008-02-19 | 2009-08-20 | Skinner George A | Method for operating a fuel cell system |
| WO2009105283A1 (en) | 2008-02-24 | 2009-08-27 | Govt. Of The United States Of America, As Represented By The Sec., Dept. Of Health And Human Service | Use of immunogenic compositions for the treatment or prevention of pathogen infections |
| BRPI0910036B8 (pt) | 2008-03-25 | 2021-05-25 | Juvaris Biotherapeutics Inc | kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina |
| US20100137235A1 (en) * | 2008-10-15 | 2010-06-03 | Mutual Pharmaceutical Company, Inc. | Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics |
| CA2761736C (en) * | 2009-05-14 | 2017-09-26 | Bayer Animal Health Gmbh | Enhanced immune response in avian species |
-
2009
- 2009-03-25 BR BRPI0910036A patent/BRPI0910036B8/pt not_active IP Right Cessation
- 2009-03-25 CA CA2719614A patent/CA2719614C/en not_active Expired - Fee Related
- 2009-03-25 WO PCT/US2009/038307 patent/WO2009120811A1/en not_active Ceased
- 2009-03-25 JP JP2011502032A patent/JP5759890B2/ja not_active Expired - Fee Related
- 2009-03-25 US US12/411,377 patent/US8945590B2/en not_active Expired - Fee Related
- 2009-03-25 EP EP09724379.4A patent/EP2257306B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2257306B1 (en) | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) | |
| EP2720717B1 (en) | Vaccine adjuvant composition comprising inulin particles | |
| US8216595B2 (en) | Powerful vaccine composition comprising lipopeptide and poly I:C as an adjuvant | |
| RU2020117033A (ru) | Комплекс, содержащий олигонуклеотид, обладающий иммуностимулирующей активностью, и его применение | |
| JP2009539965A5 (cg-RX-API-DMAC10.html) | ||
| Riese et al. | Vaccine adjuvants: key tools for innovative vaccine design | |
| JP2009511084A5 (cg-RX-API-DMAC10.html) | ||
| JP2004527264A5 (cg-RX-API-DMAC10.html) | ||
| RU2008119501A (ru) | Функциональные вирусоподоюные частицы гриппа (vlps) | |
| JP2010537961A5 (cg-RX-API-DMAC10.html) | ||
| US20150064216A1 (en) | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
| JP2013522231A5 (cg-RX-API-DMAC10.html) | ||
| WO2013043067A2 (en) | Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine | |
| JP2009511080A5 (cg-RX-API-DMAC10.html) | ||
| JP7618632B2 (ja) | 経鼻ｂ型肝炎ワクチン組成物およびその製造方法 | |
| US11590078B2 (en) | Viral immunogenic compositions | |
| KR102654379B1 (ko) | 신규한 핵산을 기반으로 하는 인플루엔자 백신 조성물 | |
| RU2018103757A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| CN115698295A (zh) | 一种疫苗试剂和接种方法 | |
| ES2615120T3 (es) | Adyuvantes peptídicos | |
| EA200870361A1 (ru) | Интраназальное или ингаляционное введение виросом | |
| Park et al. | Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant | |
| US11389526B2 (en) | Self-attenuated prophylactic and therapeutic vaccines against pathogens | |
| CN103127501A (zh) | 一种用于鸡禽流感鼻腔免疫的人工合成佐剂 | |
| RU2020122545A (ru) | Иммуностимулирующие олигонуклеотиды |